Synopsis
Synopsis
0
VMF
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
0
Weekly News Recap #Phispers


| Molecular Weight | 806.6 g/mol |
|---|---|
| Molecular Formula | C20H28N12O9PPt+ |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 1 |
| Exact Mass | 806.148777 g/mol |
| Monoisotopic Mass | 806.148777 g/mol |
| Topological Polar Surface Area | 274 A^2 |
| Heavy Atom Count | 43 |
| Formal Charge | 1 |
| Complexity | 1050 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 6 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 9601
Submission : 1992-03-26
Status : Active
Type : II
Certificate Number : CEP 2005-253 - Rev 02
Issue Date : 2025-01-22
Type : Chemical
Substance Number : 599
Status : Valid
Registration Number : 222MF10106
Registrant's Address : 435 Devon Park Drive, Suite 400, Wayne, Pennsylvania 19087 USA
Initial Date of Registration : 2010-03-19
Latest Date of Registration :
NDC Package Code : 49812-0009
Start Marketing Date : 1985-01-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
Cerata Pharmaceuticals LLP: WHO-GMP Certified Leading Manufacturer & Exporter of Steroid-Hormone & Peptide APIs From India.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-10-21
Pay. Date : 2014-03-10
DMF Number : 28046
Submission : 2014-03-09
Status : Active
Type : II
Certificate Number : CEP 2024-550 - Rev 00
Issue Date : 2025-05-23
Type : Chemical
Substance Number : 599
Status : Valid
NDC Package Code : 72659-864
Start Marketing Date : 2017-01-02
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7017
Submission : 1987-06-15
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23985
Submission : 2010-05-22
Status : Active
Type : II
Certificate Number : CEP 2010-122 - Rev 03
Issue Date : 2025-09-24
Type : Chemical
Substance Number : 599
Status : Valid

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing APIs, including hard-to-find drug substances, for pharmaceutical and biotech industries. LGM also operates as a full-service drug product ...
About the Company : Veranova is a global leader in developing and manufacturing specialist and complex APIs for pharma and biotech customers, with over 50 years of experience supporting the healthcare...
About the Company : HRV Pharma is a global manufacturer, seller, and exporter of APIs, intermediates, pellets, food-grade chemicals, food additives, and food ingredients. The company provides sourcing...
Shanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.
About the Company : Shanghai Minbiotech is specializing in the R&D and production of advanced pharmaceutical intermediates and biological APIs. There are more than 1000 square meters of R&D centers in...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.
About the Company : Willow Birch Pharma, Inc. is a premier supplier of bulk APIs to North American Compounding Pharmacies, sourcing from FDA registered and GMP manufacturers. With licenses in all 50 s...
Cerata Pharmaceuticals LLP: WHO-GMP Certified Leading Manufacturer & Exporter of Steroid-Hormone & Peptide APIs From India.
About the Company : Cerata Pharmaceuticals LLP is a WHO-GMP certified pharmaceutical API manufacturer based in Gujarat, India. We specialize in the development and manufacturing of high-quality APIs a...
About the Company : BIOTECHNICA DWC LLC has carved a niche for itself in providing value added compliance, regulatory qualification, project management and GDP guidance services to pharma companies al...

About the Company : Cipla is a global pharmaceutical company whose goal is ensuring no patient shall be denied access to high quality & affordable medicine and support. Mission: Cipla’s mission i...

About the Company : Heraeus Precious Metals business line Pharmaceutical Ingredients is specialized in the production of generic APIs as well as the exclusive synthesis of cytotoxic compounds from the...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
24 Dec 2025
Reply
27 Nov 2025
Reply
24 Sep 2025
Reply
22 Jul 2025
Reply
02 Jul 2025
Reply
18 Oct 2024
Reply
01 Aug 2024
Reply
10 Jan 2022
Reply
04 Nov 2021
Reply
11 Aug 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
86
PharmaCompass offers a list of Cisplatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cisplatin manufacturer or Cisplatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cisplatin manufacturer or Cisplatin supplier.
A Cisplatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cisplatin, including repackagers and relabelers. The FDA regulates Cisplatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cisplatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Cisplatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Cisplatin supplier is an individual or a company that provides Cisplatin active pharmaceutical ingredient (API) or Cisplatin finished formulations upon request. The Cisplatin suppliers may include Cisplatin API manufacturers, exporters, distributors and traders.
click here to find a list of Cisplatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Cisplatin DMF (Drug Master File) is a document detailing the whole manufacturing process of Cisplatin active pharmaceutical ingredient (API) in detail. Different forms of Cisplatin DMFs exist exist since differing nations have different regulations, such as Cisplatin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Cisplatin DMF submitted to regulatory agencies in the US is known as a USDMF. Cisplatin USDMF includes data on Cisplatin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cisplatin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Cisplatin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Cisplatin Drug Master File in Japan (Cisplatin JDMF) empowers Cisplatin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Cisplatin JDMF during the approval evaluation for pharmaceutical products. At the time of Cisplatin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Cisplatin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Cisplatin Drug Master File in Korea (Cisplatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cisplatin. The MFDS reviews the Cisplatin KDMF as part of the drug registration process and uses the information provided in the Cisplatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Cisplatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cisplatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Cisplatin suppliers with KDMF on PharmaCompass.
A Cisplatin CEP of the European Pharmacopoeia monograph is often referred to as a Cisplatin Certificate of Suitability (COS). The purpose of a Cisplatin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Cisplatin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Cisplatin to their clients by showing that a Cisplatin CEP has been issued for it. The manufacturer submits a Cisplatin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Cisplatin CEP holder for the record. Additionally, the data presented in the Cisplatin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Cisplatin DMF.
A Cisplatin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Cisplatin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Cisplatin suppliers with CEP (COS) on PharmaCompass.
A Cisplatin written confirmation (Cisplatin WC) is an official document issued by a regulatory agency to a Cisplatin manufacturer, verifying that the manufacturing facility of a Cisplatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cisplatin APIs or Cisplatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Cisplatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Cisplatin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cisplatin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Cisplatin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Cisplatin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Cisplatin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cisplatin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Cisplatin suppliers with NDC on PharmaCompass.
Cisplatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cisplatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Cisplatin GMP manufacturer or Cisplatin GMP API supplier for your needs.
A Cisplatin CoA (Certificate of Analysis) is a formal document that attests to Cisplatin's compliance with Cisplatin specifications and serves as a tool for batch-level quality control.
Cisplatin CoA mostly includes findings from lab analyses of a specific batch. For each Cisplatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cisplatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Cisplatin EP), Cisplatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cisplatin USP).